ALB and nasopharyngeal carcinoma: This phase I/II study aimed to determine the maximum tolerated dose (MTD) of nanoparticle albumin-bound paclitaxel (nab®-paclitaxel) plus cisplatin as treatment for metastatic nasopharyngeal carcinoma (NPC).